In light of this, it should also be investigated whether the use of non-bile acid FXR agonists, such as cilofexor, might be more suitable for the therapy of NAFLD patients with pruritus [38]. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.